New Step by Step Map For P-gb-IN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage various intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Key demo targets were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis